ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 826

Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients

Kaitlin A. Quinn1, Tunay Kuru2, Stephanie Wappel3 and Virginia D. Steen1, 1Rheumatology, Georgetown University Medical Center, Washington, DC, 2Pulmonary, Georgetown University Medical Center, Washington, DC, 3Georgetown University Medical Center, Washington, DC

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: pulmonary complications, Pulmonary Involvement, scleroderma and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary hypertension (PH) is the leading cause of scleroderma related deaths and is often detected late in the disease course. Early identification of patients with PH will lead to earlier treatment and may improve survival. The purpose of this study is to evaluate if a positive EE predicts future development of PH in a high-risk cohort of scleroderma patients.

Methods: This study included 100 scleroderma patients with features placing them at increased risk for pulmonary hypertension, including dyspnea on exertion, DLCO <60% of predicted, FVC <60% of predicted, FVC%/DLCO% >1.6, or resting right ventricular systolic pressure (RVSP) 30-50 mm Hg. In this prospective cohort study, all patients had baseline EE performed by the standard Bruce stress echocardiogram protocol with re-measurement of RVSP within 1 minute of stopping exercise. A positive EE was defined as an increase of at least 20 mmHg in the RVSP with exercise. All patients had at least one repeat echocardiogram at least one year after baseline EE. Patients were followed per standard of care and right heart catheterization (RHC) was performed in patients with a positive EE result or if PH was suspected based on symptoms. Time to follow up was defined as months to the development of resting PH, or in patients who did not develop PH, months from initial EE to the last echocardiogram.

Results: In our patient population, 12 patients were excluded as they did not have a repeat echocardiogram and 3 additional patients were excluded as they were being treated for exercise PH at the time of EE. Table 1 shows in the remaining cohort, 43 patients had a positive EE and 42 patients had a negative EE. There were no clinical demographic differences or differences in cardiopulmonary parameters between groups. In the positive EE cohort, 10 patients (23%) developed resting PH on RHC, a mean of 4 years after EE (4 with pulmonary arterial hypertension (PAH), 5 with pulmonary venous hypertension (PVH), and 1 with pulmonary hypertension associated with lung fibrosis (PH-ILD), whereas in the negative EE group, only 3 (7%) patients developed pulmonary hypertension (1 PAH, 2 PVH) (p=0.039). Of the remaining 33 patients with positive EE who did not develop resting PH, most (51%) patients continued to have a positive EE, with a mean of 5.3 years of follow up. This included 18 patients who had exercise induced pulmonary hypertension as documented on RHC, but who did not develop worsening symptoms, or changes on the echocardiogram over time.

Conclusion: While a positive EE does predict the future development of resting PH, it is not necessarily PAH, even in high-risk scleroderma patients. PVH also is associated with a positive EE. Many patients with a positive EE may have a persistently positive exercise echocardiogram without progression to resting pulmonary hypertension. A persistently negative EE may identify patients at low risk for future PH. Table 1:


Disclosure: K. A. Quinn, None; T. Kuru, None; S. Wappel, None; V. D. Steen, None.

To cite this abstract in AMA style:

Quinn KA, Kuru T, Wappel S, Steen VD. Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/exercise-echocardiography-predicts-future-development-of-pulmonary-hypertension-in-a-high-risk-cohort-of-scleroderma-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exercise-echocardiography-predicts-future-development-of-pulmonary-hypertension-in-a-high-risk-cohort-of-scleroderma-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology